Rare Hematology

Global Market Trajectory & Analytics

MCP16742

EXECUTIVE ENGAGEMENTS

OUTREACH

487
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

97
Interactions with Platform & by Email

PARTICIPANTS

19
Unique # Participated

VALIDATIONS

8
Responses Validated*

COMPETITORS

42
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

153

PAGES

225

EDITION

8

PRICE

USD $4950


  

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Rare Hematology estimated at US$13 Billion in the year 2020, is projected to reach a revised size of US$18 Billion by 2027, growing at aCAGR of 4.8% over the period 2020-2027. Plasma Derived Factors, one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$12.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Recombinant Factors segment is readjusted to a revised 4.6% CAGR for the next 7-year period.
The Rare Hematology market in the U.S. is estimated at US$3.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

SELECT PLAYERS

Alexion Pharmaceuticals, Inc.; Bayer Healthcare AG; CSL Behring; Novo Nordisk A/S; PRA Health Sciences; Shire PLC

SEGMENTS

» Age Group (Adult (18+), Pediatric (0-17)) » Indication (Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease, Other Indications) » Product Type (Plasma Derived Factors, Recombinant Factors)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Plasma Derived Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Recombinant Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hemophilia A Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hemophilia A Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemophilia A Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hemophilia B Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hemophilia B Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemophilia B Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Von Wilebrand Disease T by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Von Wilebrand Disease T by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Von Wilebrand Disease T by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Acquired Hemophilia A Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Acquired Hemophilia A Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Acquired Hemophilia A Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Adult (18+) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Pediatric (0-17) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
China Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
China Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
France Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
France Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rare Hematology by Indication - Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rare Hematology by Indication - Percentage Breakdown of Value Sales for Hemophilia A Disease, Hemophilia B Disease, Von Wilebrand Disease T, Acquired Hemophilia A Disease and Other Indications for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2012, 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com